

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/29, 15/12, C07K 14/415,</b> <b>14/435, A61K 39/35, 39/36</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/47680</b> <b>(43) International Publication Date:</b> 23 September 1999 (23.09.99)
<b>(21) International Application Number:</b> PCT/DK99/00136 <b>(22) International Filing Date:</b> 16 March 1999 (16.03.99)  <b>(30) Priority Data:</b> 0364/98                      16 March 1998 (16.03.98)                      DK  <b>(71) Applicant (for all designated States except US):</b> ALK-ABELLÓ A/S [DK/DK]; Bøge Allé 6-8, DK-2970 Hørsholm (DK).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> IPSEN, Hans, Henrik [DK/DK]; Egevej 16, DK-3400 Hillerød (DK). SPANG- FORT, Michael, Dho [DK/SE]; Høvitsmangsgatan 14, S-237 54 Helsingborg (SE). LARSEN, Jørgen, Nedergaard [DK/DK]; Nyvej 11, DK-3230 Græsted (DK).  <b>(74) Agent:</b> HOFMAN-BANG & BOUTARD, LEHMANN & REE A/S; Hans Bekkevolds Allé 7, DK-2900 Hellerup (DK).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> MUTANT RECOMBINANT ALLERGENS  <b>(57) Abstract:</b>  Novel recombinant allergens are disclosed. The allergens are non-naturally occurring mutants derived from naturally-occurring allergens. The overall $\alpha$ -carbon backbone tertiary structure is essentially preserved. Also disclosed are methods for preparing such recombinant allergens as well as uses thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## MUTANT RECOMBINANT ALLERGENS

## FIELD OF THE INVENTION

5 The present invention relates to novel recombinant allergens, which are non-naturally occurring mutants derived from naturally occurring allergens. Further, the invention relates to a method of preparing such recombinant allergens as well as to pharmaceutical  
10 compositions, including vaccines, comprising the recombinant allergens. In further embodiments, the present invention relates to methods of generating immune responses in a subject, vaccination or treatment of a subject as well as processes for preparing the  
15 compositions of the invention.

## BACKGROUND OF THE INVENTION

Genetically predisposed individuals become sensitised  
20 (allergic) to antigens originating from a variety of environmental sources, to the allergens of which the individuals are exposed. The allergic reaction occurs when a previously sensitised individual is re-exposed to the same or a homologous allergen. Allergic responses  
25 range from hay fever, rhinoconductivitis, rhinitis and asthma to systemic anaphylaxis and death in response to e.g. bee or hornet sting or insect bite. The reaction is immediate and can be caused by a variety of atopic allergens such as compounds originating from grasses,  
30 trees, weeds, insects, food, drugs, chemicals and perfumes.

However, the responses do not occur when an individual is exposed to an allergen for the first time. The initial  
35 adaptive response takes time and does usually not cause any symptoms. But when antibodies and T cells capable of

reacting with the allergen have been produced, any subsequent exposure may provoke symptoms. Thus, allergic responses demonstrate that the immune response itself can cause significant pathological states, which may be life threatening.

The antibodies involved in atopic allergy belong primarily to immunoglobulins of the IgE class. IgE binds to specific receptors on the surface of mast cells and basophils. Following complex formation of a specific allergen with IgE bound to mast cells, receptor cross-linking on the cell surface results in signalling through the receptors and the physiological response of the target cells. Degranulation results in the release of i.a. histamine, heparin, a chemotactic factor for eosinophilic leukocytes, leukotrienes C4, D4 and E4, which cause prolonged constriction of the bronchial smooth muscle cells. The resulting effects may be systemic or local in nature.

The antibody-mediated hypersensitivity reactions can be divided into four classes, namely type I, type II, type III and type IV. Type I allergic reactions is the classic immediate hypersensitivity reaction occurring within seconds or minutes following antigen exposure. These symptoms are mediated by allergen specific IgE.

Commonly, allergic reactions are observed as a response to protein allergens present e.g. in pollens, house dust mites, animal hair and dandruff, venoms, and food products.

In order to reduce or eliminate allergic reactions, carefully controlled and repeated administration of allergy vaccines is commonly used. Allergy vaccination is traditionally performed by parenteral, intranasal, or

sublingual administration in increasing doses over a fairly long period of time, and results in desensitisation of the patient. The exact immunological mechanism is not known, but induced differences in the phenotype of allergen specific T cells is thought to be of particular importance.

#### Antibody-binding epitopes (B-cell epitopes)

X-ray crystallographic analyses of Fab-antigen complexes has increased the understanding of antibody-binding epitopes. According to this type of analysis antibody-binding epitopes can be defined as a section of the surface of the antigen comprising atoms from 15-25 amino acid residues, which are within a distance from the atoms of the antibody enabling direct interaction. The affinity of the antigen-antibody interaction can not be predicted from the enthalpy contributed by van der Waals interactions, hydrogen bonds or ionic bonds, alone. The entropy associated with the almost complete expulsion of water molecules from the interface represent an energy contribution similar in size. This means that perfect fit between the contours of the interacting molecules is a principal factor underlying antigen-antibody high affinity interactions.

#### Allergy vaccination

The concept of vaccination is based on two fundamental characteristics of the immune system, namely specificity and memory. Vaccination will prime the immune system of the recipient, and upon repeated exposure to similar proteins the immune system will be in a position to respond more rigorously to the challenge of for example a microbial infection. Vaccines are mixtures of proteins intended to be used in vaccination for the purpose of

generating such a protective immune response in the recipient. The protection will comprise only components present in the vaccine and homologous antigens.

5 Compared to other types of vaccination allergy vaccination is complicated by the existence of an ongoing immune response in allergic patients. This immune response is characterised by the presence of allergen specific IgE mediating the release of allergic symptoms  
10 upon exposure to allergens. Thus, allergy vaccination using allergens from natural sources has an inherent risk of side effects being in the utmost consequence life threatening to the patient.

15 Approaches to circumvent this problem may be divided in three categories. In practise measures from more than one category are often combined. First category of measures includes the administration of several small doses over prolonged time to reach a substantial accumulated dose.  
20 Second category of measures includes physical modification of the allergens by incorporation of the allergens into gel substances such as aluminium hydroxide. Aluminium hydroxide formulation has an adjuvant effect and a depot effect of slow allergen  
25 release reducing the tissue concentration of active allergen components. Third category of measures include chemical modification of the allergens for the purpose of reducing allergenicity, i.e. IgE binding.

30 The detailed mechanism behind successful allergy vaccination remains controversial. It is, however, agreed that T cells play a key role in the overall regulation of immune responses. According to current consensus the relation between two extremes of T cell phenotypes, Th1  
35 and Th2, determine the allergic status of an individual. Upon stimulation with allergen Th1 cells secrete

interleukines dominated by interferon- $\gamma$  leading to protective immunity and the individual is healthy. Th2 cells on the other hand secrete predominantly interleukin 4 and 5 leading to IgE synthesis and eosinophilia and the individual is allergic. *In vitro* studies have indicated the possibility of altering the responses of allergen specific T cells by challenge with allergen derived peptides containing relevant T cell epitopes. Current approaches to new allergy vaccines are therefore largely based on addressing the T cells, the aim being to silence the T cells (anergy induction) or to shift the response from the Th2 phenotype to the Th1 phenotype.

In WO 97/30150 (ref. 1), a population of protein molecules is claimed, which protein molecules have a distribution of specific mutations in the amino acid sequence as compared to a parent protein. From the description, it appears that the invention is concerned with producing analogues which are modified as compared to the parent protein, but which are taken up, digested and presented to T cells in the same manner as the parent protein (naturally occurring allergens). Thereby, a modified T cell response is obtained. Libraries of modified proteins are prepared using a technique denoted PM (Parsimonious Mutagenesis).

In WO 92/02621 (ref. 2), recombinant DNA molecules are described, which molecules comprise a DNA coding for a polypeptide having at least one epitope of an allergen of trees of the order *Fagales*, the allergen being selected from *Aln g 1*, *Cor a 1* and *Bet v 1*. The recombinant molecules described herein do all have an amino acid sequence or part of an amino acid sequence that corresponds to the sequence of a naturally occurring allergen.

WO 90/11293 (ref. 3) relates i.a. to isolated allergenic peptides of ragweed pollen and to modified ragweed pollen peptides. The peptides disclosed therein have an amino acid sequence corresponding either to the sequence of the naturally occurring allergen or to naturally occurring isoforms thereof.

#### Chemical modification of allergens

Several approaches to chemical modification of allergens have been taken. Approaches of the early seventies include chemical coupling of allergens to polymers, and chemical cross-linking of allergens using formaldehyde, etc., producing the so-called 'allergoids'. The rationale behind these approaches was random destruction of IgE binding epitopes by attachment of the chemical ligand thereby reducing IgE-binding while retaining immunogenicity by the increased molecular weight of the complexes. Inherent disadvantages of 'allergoid' production are linked to difficulties in controlling the process of chemical cross-linking and difficulties in analysis and standardisation of the resulting high molecular weight complexes. 'Allergoids' are currently in clinical use and due to the random destruction of IgE binding epitopes higher doses can be administered as compared to conventional vaccines, but the safety and efficacy parameters are not improved over use of conventional vaccines.

More recent approaches to chemical modification of allergens aim at a total disruption of the tertiary structure of the allergen thus eliminating IgE binding assuming that the essential therapeutic target is the allergen specific T cell. Such vaccines contain allergen sequence derived synthetic peptides representing minimal T cells epitopes, longer peptides representing linked T

cells epitopes, longer allergen sequence derived synthetic peptides representing regions of immunodominant T cell epitopes, or allergen molecules cut in two halves by recombinant technique. Another approach based on this  
5 rationale has been the proposal of the use of "low IgE binding" recombinant isoforms. In recent years it has become clear that natural allergens are heterogeneous containing isoallergens and variants having up to approximately 25% of their amino acids substituted. Some  
10 recombinant isoallergens have been found to be less efficient in IgE binding possibly due to irreversible denaturation and hence total disruption of tertiary structure.

15 In vitro mutagenesis and allergy vaccination

Attempts to reduce allergenicity by *in vitro* site directed mutagenesis have been performed using several allergens including Der f 2 (Takai et al, ref. 4), Der p  
20 2 (Smith et al, ref. 5), a 39 kDa *Dermatophagoides farinae* allergen (Aki et al, ref. 6), bee venom phospholipase A2 (Förster et al, ref. 7), Ara h 1 (Burks et al, ref. 8), Ara h 2 (Stanley et al, ref. 9), Bet v 1 (Ferreira et al, ref. 10 and 11), birch profilin  
25 (Wiedemann et al, ref. 12), and Ory s 1 (Alvarez et al, ref. 13).

The rationale behind these approaches, again, is addressing allergen specific T cells while at the same  
30 time reducing the risk of IgE mediated side effects by reduction or elimination of IgE binding by disruption of the tertiary structure of the recombinant mutant allergen. The rationale behind these approaches does not include the concept of dominant IgE binding epitopes and  
35 it does not include the concept of initiating a new protective immune response which also involves B-cells

and antibody generation.

The article by Ferreira et al (ref. 11) describes the use of site directed mutagenesis for the purpose of reducing  
5 IgE binding. Although the three-dimensional structure of Bet v 1 is mentioned in the article the authors do not use the structure for prediction of surface exposed amino acid residues for mutation, half of which have a low degree of solvent exposure. Rather they use a method  
10 developed for prediction of functional residues in proteins different from the concept of structure based identification of conserved surface areas described here. Although the authors do discuss conservation of  $\alpha$ -carbon backbone tertiary structure this concept is not a part of  
15 the therapeutic strategy but merely included to assess *in vitro* IgE binding. Furthermore, the evidence presented is not adequate since normalisation of CD-spectra prevents the evaluation of denaturation of a proportion of the sample, which is a common problem. The therapeutic  
20 strategy described aim at inducing tolerance in allergen specific T cells and initiation of a new immune response is not mentioned.

The article by Wiedemann et al. (ref. 12) describes the  
25 use of site directed mutagenesis and peptide synthesis for the purpose of monoclonal antibody epitope characterisation. The authors have knowledge of the tertiary structure of the antigen and they use this knowledge to select a surface exposed amino acid for  
30 mutation. The algorithm used can be said to be opposite to the one described by the present inventors since an amino acid differing from homologous sequences is selected. The study demonstrates that substitution of a surface exposed amino acid has the capacity to modify the  
35 binding characteristics of a monoclonal antibody, which is not surprising considering common knowledge. The

experiments described are not designed to assess modulation in the binding of polyclonal antibodies such as allergic patients' serum IgE. One of the experiments contained do apply serum IgE and although this experiment  
5 is not suitable for quantitative assessment, IgE binding does not seem to be affected by the mutations performed.

The article by Smith et al. (ref. 5) describes the use of site directed mutagenesis for the purpose of monoclonal  
10 antibody epitope mapping and reduction of IgE binding. The authors have no knowledge of the tertiary structure and make no attempt to assess the conservation of  $\alpha$ -carbon backbone tertiary structure. The algorithm used does not ensure that amino acids selected for mutation  
15 are actually exposed to the molecular surface. Only one of the mutants described lead to a substantial reduction in IgE binding. This mutant is deficient in binding of all antibodies tested indicating that the tertiary structure is disrupted. The authors do not define a  
20 therapeutic strategy and initiation of a new immune response is not mentioned.

The article by Colombo et al. (ref. 14) describes the study of an IgE binding epitope by use of site directed  
25 mutagenesis and peptide synthesis. The authors use a three dimensional computer model structure based on the crystal structure of a homologous protein to illustrate the presence of the epitope on the molecular surface. The further presence of an epitope on a different allergen  
30 showing primary structure homology is addressed using synthetic peptides representing the epitope. The therapeutic strategy is based on treatment using this synthetic peptide representing a monovalent IgE binding epitope. Conserved surface areas between homologous  
35 allergens as well as the therapeutic concept of initiating a new protective immune response are not

mentioned.

The article by Spangfort *et al.* (ref. 15) describes the three-dimensional structure and conserved surface exposed patches of the major birch allergen. The article does not mention major IgE binding epitopes nor site directed mutagenesis, neither is therapeutic application addressed.

In none of the studies described above is IgE binding reduced by substitution of surface exposed amino acids while conserving  $\alpha$ -carbon backbone tertiary structure. The rationale behind above-mentioned approaches does not include the concept of dominant IgE binding epitopes and it does not include the therapeutic concept of initiating a new protective immune response.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows mutant-specific oligonucleotide primers used for *Bet v 1* mutant number 1. Mutated nucleotides are underlined.

Figure 2 shows two generally applicable primers (denoted "all-sense" and "all non-sense"), which were synthesised and used for all mutants.

Figure 3 shows an overview of all *Bet v 1* mutations.

Figure 4 shows the inhibition of the binding of biotinylated recombinant *Bet v 1* to serum IgE from a pool of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* Glu45Ser mutant.

Figure 5 shows the inhibition of the binding of biotinylated recombinant *Bet v 1* to serum IgE from a pool

of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* mutant Asn28Thr+Lys32Gln.

Figure 6 shows the inhibition of the binding of  
5 biotinylated recombinant *Bet v 1* to serum IgE from a pool of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* Pro108Gly mutant.

Figure 7 shows the inhibition of the binding of  
10 biotinylated recombinant *Bet v 1* to serum IgE from a pool of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* Glu60Ser mutant.

Figure 8 shows the CD spectra of recombinant and  
15 Triple-patch mutant, recorded at close to equal concentrations.

Figure 9 shows the inhibition of the binding of  
20 biotinylated recombinant *Bet v 1* to serum IgE from a pool of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* Triple-patch mutant.

Figure 10 shows solvent accessibility of individually  
25 aligned antigen 5 residues and alignment of *Vespula* antigen 5 sequences (left panel). On the right panel of Figure 10 is shown the molecular surface of antigen 5 with conserved areas among *Vespula* antigen 5:s.

Figure 11 shows the sequence of the primer corresponding  
30 to the amino terminus of *Ves v 5* derived from the sense strand. The sequence of the downstream primer is derived from the non-sense strand.

Figure 12 shows two generally applicable primers (denoted  
35 "all sense" and "all non-sense", which were synthesised and used for all mutants.

Figure 13 shows an overview of all Ves v 5 mutations.

Figure 14 shows the inhibition of the binding of  
5 biotinylated recombinant Ves v 5 to serum IgE from a pool  
of allergic patients by non-biotinylated Ves v 5 and by  
Ves v 5 Lys72Ala mutant.

## OBJECT OF THE INVENTION

10

### Rationale behind the present invention

The current invention is based on a unique rationale.  
According to this rationale the mechanism of successful  
15 allergy vaccination is not an alteration of the ongoing  
Th2-type immune response, but rather a parallel  
initiation of a new Th1-type immune response involving  
tertiary epitope recognition by B-cells and antibody  
formation. This model is supported by the observation  
20 that levels of specific IgE are unaffected by successful  
vaccination treatment, and that successful treatment is  
often accompanied by a substantial rise in allergen  
specific IgG4. In addition, studies of nasal biopsies  
before and after allergen challenge do not show a  
25 reduction in T cells with the Th2-like phenotype, but  
rather an increase in Th1-like T cells are observed. When  
the vaccine (or pharmaceutical compositions) is  
administered through another route than the airways, it  
is hypothesised, that the new Th1-like immune response  
30 evolves in a location physically separated from the  
ongoing Th2 response thereby enabling the two responses  
to exist in parallel.

Another important aspect of the rationale behind the  
35 current invention is the assertion of the existence of  
dominant IgE binding epitopes. It is proposed that these

dominant IgE binding epitopes are constituted by tertiary structure dependent coherent surface areas large enough to accommodate antibody binding and conserved among isoallergens, variants, and/or homologous allergens from related species. The existence of cross-reactive IgE capable of binding similar epitopes on homologous allergens is supported by the clinical observation that allergic patients often react to several closely related species, e.g. alder, birch, and hazel, multiple grass species, or several species of the house dust mite genus *Dermatophagoides*. It is furthermore supported by laboratory experiments demonstrating IgE cross-reactivity between homologous allergens from related species and the capacity of one allergen to inhibit the binding of IgE to homologous allergens (Ipsen et al. 1992, ref. 16). It is well known that exposure and immune responses are related in a dose dependent fashion. Based on the combination of these observations it is hypothesised that conserved surface areas are exposed to the immune system in higher doses than non-conserved surface areas resulting in the generation of IgE antibodies with higher affinities, hence the term 'dominant IgE binding epitopes'.

According to this rationale it is essential that the allergen has an  $\alpha$ -carbon backbone tertiary structure which essentially is the same as that of the natural allergen, thus ensuring conservation of the surface topology of areas surrounding conserved patches representing targets for mutagenesis aimed at reducing IgE binding. By fulfilling these criteria the allergen has the potential to be administered in relatively higher doses improving its efficacy in generating a protective immune response without compromising safety.

## SUMMARY OF THE INVENTION

The present invention relates to the introduction of artificial amino acid substitutions into defined critical positions while retaining the  $\alpha$ -carbon backbone tertiary structure of the allergen.

5

The invention provides a recombinant allergen, which is a non-naturally occurring mutant derived from a naturally occurring allergen, wherein at least one surface-exposed, conserved amino acid residue of a B cell epitope is substituted by another residue which does not occur in the same position in the amino acid sequence of any known homologous protein within the taxonomic order from which said naturally occurring allergen originates, said mutant allergen having essentially the same  $\alpha$ -carbon backbone tertiary structure as said naturally occurring allergen, and the specific IgE binding to the mutated allergen being reduced as compared to the binding to said naturally occurring allergen.

20 Such recombinant allergen is obtainable by

a) identifying amino acid residues in a naturally occurring allergen which are conserved with more than 70% identity in all known homologous proteins within the taxonomic order from which said naturally occurring allergen originates;

b) defining at least one patch of conserved amino acid residues being coherently connected over at least 400  $\text{\AA}^2$  of the surface of the three-dimensional of the allergen molecule as defined by having a solvent accessibility of at least 20%, said at least one patch comprising at least one B cell epitope; and

35 c) substituting at least one amino acid residue in said at least one patch by another amino acid being non-con-

servative in the particular position while essentially preserving the overall  $\alpha$ -carbon backbone tertiary structure of the allergen molecule.

- 5 Specific IgE binding to the mutated allergen is preferably reduced by at least 5%, preferably at least 10% in comparison to naturally-occurring isoallergens or similar recombinant proteins in an immuno assay with sera from source-specific IgE reactive allergic patients or  
10 pools thereof.

Recombinant allergens according to the invention may suitably be derived from inhalation allergens originating i.a. from trees, grasses, herbs, fungi, house dust mites,  
15 cockroaches and animal hair and dandruff. Important pollen allergens from trees, grasses and herbs are such originating from the taxonomic orders of *Fagales*, *Oleales* and *Pinales* including i.a. birch (*Betula*), alder (*Alnus*), hazel (*Corylus*), hornbeam (*Carpinus*) and olive (*Olea*),  
20 the order of *Poales* including i.a. grasses of the genera *Lolium*, *Phelum*, *Poa*, *Cynodon*, *Dactylis* and *Secale*, the orders of *Asterales* and *Urticales* including i.a. herbs of the genera *Ambrosia* and *Artemisia*. Important inhalation allergens from fungi are i.a. such originating from the  
25 genera *Alternaria* and *Cladosporium*. Other important inhalation allergens are those from house dust mites of the genus *Dermatophagoides*, those from cockroaches and those from mammals such as cat, dog and horse. Further, recombinant allergens according to the invention may be  
30 derived from venom allergens including such originating from stinging or biting insects such as those from the taxonomic order of *Hymenoptera* including bees (superfamily *Apidae*), wasps (superfamily *Vespidea*), and ants (superfamily *Formicoidae*).

35

Specific allergen components include e.g. *Bet v 1* (*B.*

verrucosa, birch), *Aln g 1* (*Alnus glutinosa*, alder), *Cor a 1* (*Corylus avelana*, hazel) and *Car b 1* (*Carpinus betulus*, hornbeam) of the *Fagales* order. Others are *Cry j 1* (*Pinales*), *Amb a 1* and 2, , *Art v 1* (*Asterales*), *Par j 1* (*Urticales*), *Ole e 1* (*Oleales*), *Ave e 1*, *Cyn d 1*, *Dac g 1*, *Fes p 1*, *Hol l 1*, *Lol p 1* and 5, *Pas n 1*, *Phl p 1* and 5, *Poa p 1*, 2 and 5, *Sec c 1* and 5, and *Sor h 1* (various grass pollens), *Alt a 1* and *Cla h 1* (fungi), *Der f 1* and 2, *Der p 1* and 2 (house dust mites, *D. farinae* and *D. pteronyssinus*, respectively), *Bla g 1* and 2, *Per a 1* (cockroaches, *Blatella germanica* and *Periplaneta americana*, respectively), *Fel d 1* (cat), *Can f 1* (dog), *Equ c 1*, 2 and 3 (horse), *Apis m 1* and 2 (honeybee), *Ves g 1*, 2 and 5, *Pol a 1*, 2 and 5 (all wasps) and *Sol i 1*, 2, 3 and 4 (fire ant).

In one embodiment, the recombinant allergen is derived from *Bet v 1*. Examples of substitutions are Thr10Pro, Asp25Gly, (Asn28Thr + Lys32Gln), Glu45Ser, Asn47Ser, Lys55Asn, Thr77Ala, Pro108Gly and (Asn28Thr, Lys32Gln, Glu45Ser, Pro108Gly. As apparent, the recombinant allergens may have one or more substitutions.

In another embodiment, the recombinant allergen is derived from a venom allergen from the taxonomic order of Vespidae, Apidae and Formicoidae.

In a further embodiment, the recombinant allergen is derived from *Ves v 5*. Examples of substitutions are Lys72Ala and Tyr96Ala. As apparent, the recombinant allergens may have one or more substitutions.

The present invention also provides a method of preparing a recombinant allergen as defined herein, comprising

35

a) identifying amino acid residues in a naturally

occurring allergen which are conserved with more than 70% identity in all known homologous proteins within the taxonomic order from which said naturally occurring allergen originates;

5

b) defining at least one patch of conserved amino acid residues being coherently connected over at least 400 Å<sup>2</sup> of the surface of the three-dimensional structure of the allergen molecule as defined by having a solvent  
10 accessibility of at least 20 %, said at least one patch comprising at least one B cell epitope, and

c) substituting at least one amino acid residue in said at least one patch by another amino acid being non-conservative in the particular position while essentially  
15 preserving the overall α-carbon backbone tertiary structure of the allergen molecule.

In this method the best results are obtained by ranking  
20 the amino acid residues of said at least one patch with respect to solvent accessibility and substituting one or more amino acids among the more solvent accessible ones.

Generally, in the method according to the invention the  
25 substitution of one or more amino acid residues in said B cell epitope or said at least one patch is carried out by site-directed mutagenesis.

Conservation of α-carbon backbone tertiary structure is  
30 best determined by obtaining identical structures by x-ray crystallography or NMR before and after mutagenesis. In absence of structural data describing the mutant indistinguishable CD-spectra or immunochemical data, e.g. antibody reactivity, may render conservation of α-carbon  
35 backbone tertiary structure probable, if compared to the data obtained by analysis of a structurally determined

molecule.

Further, the present invention provides a pharmaceutical composition comprising a recombinant allergen as defined  
5 herein in combination with a pharmaceutically acceptable carrier and/or excipient, and optionally an adjuvant.

Such pharmaceutical composition may be in the form of a vaccine against allergic reactions elicited by a  
10 naturally occurring allergen in patients suffering from allergy.

In a further aspect, the present invention relates to a method of generating an immune response in a subject,  
15 which method comprises administering to the subject at least one recombinant allergen as defined herein, or a pharmaceutical composition comprising at least one recombinant allergen as defined herein.

20 The pharmaceutical composition of the invention can be prepared by a process comprising mixing at least one recombinant allergen as defined herein with pharmaceutically acceptable substances and/or excipients.

25 In a particular embodiment, the present invention concerns the vaccination or treatment of a subject, which vaccination or treatment comprises administering to the subject at least one recombinant allergen as defined herein or a pharmaceutical composition as defined herein.

30 The pharmaceutical compositions of the invention are obtainable by the process defined above.

In another embodiment, the recombinant allergens of the  
35 invention are suitable for use in a method for the treatment, prevention or alleviation of allergic

reactions, such method comprising administering to a subject a recombinant allergen as defined herein or a pharmaceutical composition as defined herein.

5 DETAILED DESCRIPTION OF THE INVENTION

Criteria for substitution

For molecules for which the tertiary structure has been  
10 determined (e.g. by x-ray crystallography, or NMR electron microscopy), the mutant carrying the substituted amino acid(s) should preferably fulfil the following criteria:

15 1. The overall  $\alpha$ -carbon backbone tertiary structure of the molecule should be conserved. Conserved is defined as an average root mean square deviation of the atomic coordinates comparing the structures below 2Å. This is important for two reasons: a) It is anticipated that the  
20 entire surface of the natural allergen constitutes an overlapping continuum of potential antibody-binding epitopes. The majority of the surface of the molecule is not affected by the substitution(s), and thus retain its antibody-binding properties, which is important for the  
25 generation of new protective antibody specificities being directed at epitopes present also on the natural allergen. b) Stability, both concerning shelf-life and upon injection into body fluids.

30 2. The amino acid(s) to be substituted should be located at the surface, and thus be accessible for antibody-binding. Amino acids located on the surface are defined as amino acids in the three-dimensional structure having a solvent (water) accessibility of at least 20%, suitably  
35 20-80%, more suitably 30-80%. Solvent accessibility is defined as the area of the molecule accessible to a

sphere with a radius comparable to a solvent (water,  $r = 1.4 \text{ \AA}$ ) molecule.

3. The substituted amino acid(s) should be located in conserved patches larger than  $400 \text{ \AA}^2$ . Conserved patches are defined as coherently connected areas of surface exposed conserved amino acid residues and backbone. Conserved amino acid residues are defined by sequence alignment of all known (deduced) amino acid sequences of homologues proteins within the taxonomical order. Amino acid positions having identical amino acid residues in more than 90% of the sequences are considered conserved. Conserved patches are expected to contain epitopes to which the IgE of the majority of patients is directed.

15

4. Within the conserved patches amino acids for mutagenesis should preferentially be selected among the most solvent (water) accessible ones located preferably near the centre of the conserved patch.

20

Preferentially, a polar amino acid residue is substituted by another polar residue, and a non-polar amino acid residue is substituted by another non-polar residue.

25 Preparation of vaccines is generally well-known in the art. Vaccines are typically prepared as injectables either as liquid solutions or suspensions. Such vaccine may also be emulsified or formulated so as to enable nasal administration. The immunogenic component in question (the recombinant allergen as defined herein) may suitably be mixed with excipients which are pharmaceutically acceptable and further compatible with the active ingredient. Examples of suitable excipients are water, saline, dextrose, glycerol, ethanol and the like as well as combinations thereof. The vaccine may additionally contain other substances such as wetting

30

35

agents, emulsifying agents, buffering agents or adjuvants enhancing the effectiveness of the vaccine.

Vaccines are most frequently administered parenterally by  
5 subcutaneous or intramuscular injection. Formulations  
which are suitable for administration by another route  
include oral formulations and suppositories. Vaccines for  
oral administration may suitably be formulated with  
excipients normally employed for such formulations, e.g.  
10 pharmaceutical grades of mannitol, lactose, starch,  
magnesium stearate, sodium saccharine, cellulose,  
magnesium carbonate and the like. The composition can be  
formulated as solutions, suspensions, emulsions, tablets,  
pills, capsules, sustained release formulations,  
15 aerosols, powders, or granulates.

The vaccines are administered in a way so as to be  
compatible with the dosage formulation and in such amount  
as will be therapeutically effective and immunogenic. The  
20 quantity of active component contained within the vaccine  
depends on the subject to be treated, i.e. the capability  
of the subject's immune system to respond to the  
treatment, the route of administration and the age and  
weight of the subject. Suitable dosage ranges can vary  
25 within the range from about 0.0001 µg to 1000 µg.

As mentioned above, an increased effect may be obtained  
by adding adjuvants to the formulation. Examples of such  
adjuvants are aluminum hydroxide and phosphate (alum) as  
30 a 0.05 to 0.1 percent solution in phosphate buffered  
saline, synthetic polymers of sugars used as 0.25 percent  
solution. Mixture with bacterial cells such as *C. parvum*,  
endotoxins or lipopolysaccharide components of gram-  
negative bacteria, emulsion in physiologically acceptable  
35 oil vehicles such as mannide monooleate (Aracel A) or  
emulsion with 20 percent solution of a perfluorocarbon

(e.g. Fluosol-DA) used as a block substitute may also be employed. Other adjuvants such as Freund's complete and incomplete adjuvants as well as QuilA and RIBI may also be used.

5

Most often, multiple administrations of the vaccine will be necessary to ensure an effect. Frequently, the vaccine is administered as an initial administration followed by subsequent inoculations or other administrations. The number of vaccinations will typically be in the range of from 1 to 50, usually not exceeding 35 vaccinations. Vaccination will normally be performed from biweekly to bimonthly for a period of 3 months to 5 years. This is contemplated to give desired level of prophylactic or therapeutic effect.

The recombinant allergen may be used as a pharmaceutical preparation, which is suitable for providing a certain protection against allergic responses during the period of the year where symptoms occur (prophylaxis). Usually, the treatment will have to be repeated every year to maintain the protective effect. Preparations formulated for nasal application are particularly suited for this purpose.

25

The present invention is further illustrated by the following non-limiting examples.

#### EXAMPLES

30

##### EXAMPLE 1

##### Identification of common epitopes within Fagales pollen allergens

35

The major birch pollen allergen Bet v 1 shows about 90%

amino acid sequence identity with major allergens from pollens of taxonomically related trees, i.e *Fagales* (for instance hazel and hornbeam) and birch pollen allergic patients often show clinical symptoms of allergic cross-reactivity towards these *Bet v 1* homologous proteins.

*Bet v 1* also shows about 50-60% sequence identity with allergic proteins present in certain fruits (for instance apple and cherry) and vegetables (for instance celery and carrot) and there are clinical evidence for allergic cross-reactivity between *Bet v 1* and these food related proteins.

In addition, *Bet v 1* shares significant sequence identity (20-40%) with a group of plant proteins called pathogenesis-related proteins (PR-10), however there are no reports of allergic cross-reactivity towards these PR-10 proteins.

Molecular modelling suggests that the structures of *Fagales* and food allergens and PR-10 proteins are close to be identical with the *Bet v 1* structure.

The structural basis for allergic *Bet v 1* cross-reactivity was reported in (Gajhede et al 1996, ref. 17) where three patches on the molecular surface of *Bet v 1* could be identified to be common for the known major tree pollen allergens. Thus, any IgE recognising these patches on *Bet v 1* would be able to cross-react and bind to other *Fagales* major pollen allergens and give rise to allergic symptoms. The identification of these common patches was performed after alignment of all known amino acid sequences of the major tree pollen allergens in combination with an analysis of the molecular surface of *Bet v 1* revealed by the  $\alpha$ -carbon backbone tertiary structure reported in ref. 17. In addition, the patches

were defined to have a certain minimum size ( $>400 \text{ \AA}^2$ ) based on the area covered by an antibody upon binding.

5     Selection of amino acid residues for site-directed mutagenesis

Amino acid residues for site-directed mutagenesis were selected among residues present in *Bet v 1* specific areas and the common patches since modifications of these is  
10     expected to affect the binding of serum IgE from the majority of patients showing clinical tree pollen allergic cross-reactivity.

The relative orientation and percentage of solvent-exposure of each amino acid residue within respective  
15     patch was calculated based on their atomic coordinates. Residues having a low degree of solvent exposure ( $<20\%$ ) were not regarded relevant for mutagenesis due to the possible disruption of the structure or lack of antibody  
20     interaction. The remaining residues were ranked according to their degree of solvent-exposure.

Sequence alignment

25     Sequences homologous to the query sequence (*Bet v 1* No. 2801, WHO IUIS Nomenclature Subcommittee on Allergens) were derived from GenBank and EMBL sequence databases by a BLAST search (Altschul et al., ref. 18). All sequences with BLAST reported probabilities less than 0.1 were  
30     taken into consideration and one list were constructed containing a non-redundant list of homologous sequences. These were aligned by CLUSTAL W (Higgins et al., ref. 19) and the percentage identity were calculated for each position in the sequence considering the complete list or  
35     taxonomically related species only. A total of 122 sequences were homologous to *Bet v 1* No. 2801 of which 57

sequences originates from taxonomically related species.

#### Cloning of the gene encoding Bet v 1

5 RNA was prepared from *Betula verrucosa* pollen (Allergon, Sweden) by phenol extraction and LiCl precipitation. Oligo(dT)-cellulose affinity chromatography was performed batch-wise in Eppendorph tubes, and double-stranded cDNA was synthesised using a commercially available kit.  
10 (Amersham). DNA encoding Bet v 1 was amplified by PCR and cloned. In brief, PCR was performed using cDNA as template, and primers designed to match the sequence of the cDNA in positions corresponding to the amino terminus of Bet v 1 and the 3'-untranslated region, respectively.  
15 The primers were extended in the 5'-ends to accommodate restriction sites (*Nco*I and *Hind*III) for directional cloning into pKK233-2.

#### Subcloning into pMAL-c

20

The gene encoding Bet v 1 was subsequently subcloned into the maltose binding protein fusion vector pMAL-c (New England Biolabs). The gene was amplified by PCR and subcloned in frame with *malE* to generate maltose binding  
25 protein (MBP)-Bet v 1 protein fusion operons in which MBP and Bet v 1 were separated by a factor  $X_a$  protease cleavage site positioned to restore the authentic aminoterminal sequence of Bet v 1 upon cleavage, as described in ref. 15. In brief, PCR was performed using  
30 pKK233-3 with Bet v 1 inserted as template and primers corresponding to the amino- and carboxyterminus of the protein, respectively. The promoter proximal primer was extended in the 5'-end to accommodate 4 codons encoding an in frame factor  $X_a$  protease cleavage site. Both  
35 primers were furthermore extended in the 5'-ends to accommodate restriction sites (*Kpn*I) for cloning. The

*Bet v 1* encoding genes were subcloned using 20 cycles of PCR to reduce the frequency of PCR artefacts.

#### In vitro mutagenesis

5

*In vitro* mutagenesis was performed by PCR using recombinant pMAL-c with *Bet v 1* inserted as template. Each mutant *Bet v 1* gene was generated by 3 PCR reactions using 4 primers.

10

Two mutation-specific oligonucleotide primers were synthesised accommodating each mutation, one for each DNA strand, see Figs. 1 and 2, Using the mutated nucleotide(s) as starting point both primers were extended 7 nucleotides in the 5'-end and 15 nucleotides in the 3'-end. The extending nucleotides were identical in sequence to the *Bet v 1* gene in the actual region.

Two generally applicable primers (denoted "all-sense" and "all non-sense" in Figure 2) were furthermore synthesised and used for all mutants. These primers were 15 nucleotides in length and correspond in sequence to regions of the pMAL-c vector approximately 1 kilobase upstream and downstream from the *Bet v 1*. The sequence of the upstream primer is derived from the sense strand and the sequence of the downstream primer is derived from the non-sense strand, see Fig. 2.

Two independent PCR reactions were performed essentially according to standard procedures (Saiki et al 1988, ref. 20) with the exception that only 20 temperature cycles were performed in order to reduce the frequency of PCR artefacts. Each PCR reaction used pMAL-c with *Bet v 1* inserted as template and one mutation-specific and one generally applicable primer in meaningful combinations.

Introduction of the four amino acid substitutions (Asn28Thr, Lys32Gln, Glu45Ser, Pro108Gly) in the Triple-patch mutant were performed like described above in a step by step process. First the Glu45Ser mutation then  
5 the Pro108Gly mutation and last the Asn28Thr, Lys32Gln mutations were introduced using pMAL-c with inserted *Bet v 1* No. 2801, *Bet v 1* (Glu45Ser), *Bet v 1* (Glu45Ser, Pro108Gly) as templates, respectively.

10 The PCR products were purified by agarose gel electrophoresis and electro-elution followed by ethanol precipitation. A third PCR reaction was performed using the combined PCR products from the first two PCR reactions as template and both generally applicable  
15 primers. Again, 20 cycles of standard PCR were used. The PCR product was purified by agarose gel electrophoresis and electro-elution followed by ethanol precipitation, cut with restriction enzymes (*BsiWI/EcoRI*), and ligated directionally into pMAL-c with *Bet v 1* inserted  
20 restricted with the same enzymes.

Figure 3 shows an overview of all 9 *Bet v 1* mutations, which are as follows

25 Thr10Pro, Asp25Gly, Asn28Thr + Lys32Gln, Glu45Ser, Asn47Ser, Lys55Asn, Glu60Ser (non-patch), Thr77Ala and Pro108Gly. An additional four mutant with four mutations was also prepared (Asn28Thr, Lys32Gln, Glu45Ser, Pro108Gly). Of these, five were selected for further  
30 testing: Asn28Thr + Lys32Gln, Glu45Ser, Glu60Ser, Pro108Gly and the Triple-patch mutant Asn28Thr, Lys32Gln, Glu45Ser, Pro108Gly.

#### Nucleotide sequencing

35

Determination of the nucleotide sequence of the *Bet v 1*

encoding gene was performed before and after subcloning, and following *in vitro* mutagenesis, respectively.

5 Plasmid DNA's from 10 ml of bacterial culture grown to saturation overnight in LB medium supplemented with 0.1 g/l ampicillin were purified on Qiagen-tip 20 columns and sequenced using the Sequenase version 2.0 DNA sequencing kit (USB) following the recommendations of the suppliers.

10 Expression and purification of recombinant Bet v 1 and mutants

Recombinant Bet v 1 (Bet v 1 No. 2801 and mutants) were over-expressed in *Escherichia coli* DH 5a fused to maltose-binding protein and purified as described in ref. 15. Briefly, recombinant *E.coli* cells were grown at 37°C to an optical density of 1.0 at 436 nm, whereupon expression of the Bet v 1 fusion protein was induced by addition of IPTG. Cells were harvested by centrifugation 20 3 hours post-induction, re-suspended in lysis buffer and broken by sonication. After sonication and additional centrifugation, recombinant fusion protein was isolated by amylose affinity chromatography and subsequently cleaved by incubation with Factor Xa (ref. 15). After F 25 Xa cleavage, recombinant Bet v 1 was isolated by gelfiltration and if found necessary, subjected to another round of amylose affinity chromatography in order to remove trace amounts of maltose-binding protein.

30 Purified recombinant Bet v 1 was concentrated by ultrafiltration to about 5 mg/ml and stored at 4 °C. The final yields of the purified recombinant Bet v 1 preparations were between 2-5 mg per litre *E. coli* cell culture.

35

The purified recombinant Bet v 1 preparations appeared as

single bands after silver-stained SDS-polyacrylamide electrophoresis with an apparent molecular weight of 17.5 kDa. N-terminal sequencing showed the expected sequences as derived from the cDNA nucleotide sequences and  
5 quantitative amino acid analysis showed the expected amino acid compositions.

We have previously shown (ref. 15) that recombinant Bet v 1 No. 2801 is immunochemically indistinguishable from  
10 naturally occurring Bet v 1.

Immunoelectrophoresis using rabbit polyclonal antibodies

The seven mutant Bet v 1 were produced as recombinant Bet  
15 v 1 proteins and purified as described above and tested for their reactivity towards polyclonal rabbit antibodies raised against Bet v 1 isolated from birch pollen. When analysed by immunoelectrophoresis (rocket-line immunoelectrophoresis) under native conditions, the  
20 rabbit antibodies were able to precipitate all mutants, indicating that the mutants had conserved  $\alpha$ -carbon backbone tertiary structure.

These results suggested that non-naturally occurring  
25 substitutions introduced on the molecular surface of Bet v 1 can reduce a polyclonal antibody response raised against naturally occurring Bet v 1 without distortion of the overall  $\alpha$ -carbon backbone tertiary allergen structure. In order to analyse the effect on human  
30 polyclonal IgE-response, the mutants Glu45Ser, Pro108Gly, Asn28Thr+Lys32Gln and Glu60Ser were selected for further analysis.

Bet v 1 Glu45Ser mutant

35

Glutamic acid in position 45 show a high degree of

solvent-exposure (40%) and is located in a molecular surface patch common for *Fagales* allergens (patch I). A serine residue was found to occupy position 45 in some of the *Bet v 1* homologous PR-10 proteins arguing for that glutamic acid can be replaced by serine without distortion of the  $\alpha$ -carbon backbone tertiary structure. In addition, as none of the known *Fagales* allergen sequences have serine in position 45, the substitution of glutamic acid with serine gives rise to a non-naturally occurring *Bet v 1* molecule.

T cell proliferation assay using recombinant Glu45Ser *Bet v 1* mutant

The analysis was carried out as described in Spangfort et al 1996a. It was found that recombinant *Bet v 1* Glu45Ser mutant was able to induce proliferation in T cell lines from three different birch pollen allergic patients with stimulation indices similar to recombinant and naturally occurring.

Crystallisation and structural determination of recombinant Glu45Ser *Bet v 1*

Crystals of recombinant Glu45Ser *Bet v 1* were grown by vapour diffusion at 25°C, essentially as described in (Spangfort et al 1996b, ref. 21). Glu45Ser *Bet v 1*, at a concentration of 5 mg/ml, was mixed with an equal volume of 2.0 M ammonium sulphate, 0.1 M sodium citrate, 1% (v/v) dioxane, pH 6.0 and equilibrated against 100x volume of 2.0 M ammonium sulfate, 0.1 M sodium citrate, 1% (v/v) dioxane, pH 6.0. After 24 hours of equilibration, crystal growth was induced by applying the seeding technique described in ref. 21, using crystals of recombinant wild-type *Bet v 1* as a source of seeds.

After about 2 months, crystals were harvested and analysed using X-rays generated from a Rigaku rotating anode as described in ref. 21 and the structure was solved using molecular replacement.

5

#### Structure of Bet v 1 Glu45Ser mutant

The structural effect of the mutation was addressed by growing three-dimensional Bet v 1 Glu45Ser protein crystals diffracting to 3.0 Å resolution when analysed by X-rays generated from a rotating anode. The substitution of glutamic acid to serine in position 45 was verified by the Bet v 1 Glu45Ser structure electron density map which also showed that the overall  $\alpha$ -carbon backbone tertiary structure is preserved.

15

#### IgE-binding properties of Bet v 1 Glu45Ser mutant

The IgE-binding properties of Bet v 1 Glu45Ser mutant was compared with recombinant Bet v 1 in a fluid-phase IgE-inhibition assay using a pool of serum IgE derived from birch allergic patients.

20

Recombinant Bet v 1 no. 2801 was biotinylated at a molar ratio of 1:5 (Bet v 1 no. 2801:biotin). The inhibition assay was performed as follows: a serum sample (25  $\mu$ l) was incubated with solid phase anti IgE, washed, re-suspended and further incubated with a mixture of biotinylated Bet v 1 no. 2801 (3.4 nM) and a given mutant (0-28.6 nM). The amount of biotinylated Bet v 1 no. 2801 bound to the solid phase was estimated from the measured RLU after incubation with acridinium ester labelled streptavidin. The degree of inhibition was calculated as the ratio between the RLU's obtained using buffer and mutant as inhibitor.

30

35

Figure 4 shows the inhibition of the binding of biotinylated recombinant *Bet v 1* to serum IgE from a pool of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* Glu45Ser mutant.

5

There is a clear difference in the amount of respective recombinant proteins necessary to reach 50% inhibition of the binding to serum IgE present in the serum pool.

Recombinant *Bet v 1* reaches 50% inhibition at about 6.5 ng whereas the corresponding concentration for *Bet v 1* Glu45Ser mutant is about 12 ng. This show that the point mutation introduced in *Bet v 1* Glu45Ser mutant lowers the affinity for specific serum IgE by a factor of about 2.

The maximum level of inhibition reached by the *Bet v 1* Glu45Ser mutant is clearly lower compared to recombinant *Bet v 1*. This may indicate that after the Glu45Ser substitution, some of the specific IgE present in the serum pool are unable to recognise the *Bet v 1* Glu45Ser mutant.

20

*Bet v 1* mutant Asn28Thr+Lys32Gln

Aspartate and lysine in positions 28 and 32, respectively show a high degree of solvent-exposure (35% and 50%, respectively) and are located in a molecular surface patch common for *Fagales* allergens (patch II). In the structure, aspartate 28 and lysine 32 are located close to each other on the molecular surface and most likely interact via hydrogen bonds. A threonine and a glutamate residue were found to occupy positions 28 and 32, respectively in some of the *Bet v 1* homologous PR-10 proteins arguing for that aspartate and lysine can be replaced with threonine and glutamate, respectively without distortion of the  $\alpha$ -carbon backbone tertiary structure. In addition, as none of the naturally occurring isoallergen sequences have threonine and

glutamate in positions 28 and 32, respectively, the substitutions gives rise to a non-naturally occurring *Bet v 1* molecule.

5    IgE-binding properties of *Bet v 1* mutant  
     Asn28Thr+Lys32Gln

The IgE-binding properties of mutant Asn28Thr+Lys32Gln was compared with recombinant *Bet v 1* in a fluid-phase  
10    IgE-inhibition assay using the pool of serum IgE derived from birch allergic patients described above.

Figure 5 shows the inhibition of the binding of biotinylated recombinant *Bet v 1* to serum IgE from a pool  
15    of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* mutant Asn28Thr+Lys32Gln.

There is a clear difference in the amount of respective recombinant proteins necessary to reach 50% inhibition of  
20    the binding to serum IgE present in the serum pool. Recombinant *Bet v 1* reaches 50% inhibition at about 6.5 ng whereas the corresponding concentration for *Bet v 1* mutant Asn28Thr+Lys32Gln is about 12 ng. This show that the point mutations introduced in *Bet v 1* mutant  
25    Asn28Thr+Lys32Gln lowers the affinity for specific serum IgE by a factor of about 2.

The maximum level of inhibition reached by the *Bet v 1* mutant Asn28Thr+Lys32Gln mutant is clearly lower compared  
30    to recombinant *Bet v 1*. This may indicate that after the Asn28Thr+Lys32Gln substitutions, some of the specific IgE present in the serum pool are unable to recognise the *Bet v 1* mutant Asn28Thr+Lys32Gln.

35    *Bet v 1* mutant Pro108Gly

Proline in position 108 show a high degree of solvent-exposure (60%) and is located in a molecular surface patch common for *Fagales* allergens (patch III). A glycine residue was found to occupy position 108 in some of the  
5 *Bet v 1* homologous PR-10 proteins arguing for that proline can be replaced with glycine without distortion of the  $\alpha$ -carbon backbone tertiary structure. In addition, as none of the naturally occurring isoallergen sequences  
~ have glycine in position 108, the substitution of proline  
10 with glycine gives rise to a non-naturally occurring *Bet v 1* molecule.

IgE-binding properties of *Bet v 1* Pro108Gly mutant

- 15 The IgE-binding properties of *Bet v 1* Pro108Gly mutant was compared with recombinant *Bet v 1* in a fluid-phase IgE-inhibition assay using the pool of serum IgE derived from birch allergic patients described above.
- 20 Figure 6 shows the inhibition of the binding of biotinylated recombinant *Bet v 1* to serum IgE from a pool of allergic patients by non-biotinylated *Bet v 1* and by *Bet v 1* Pro108Gly mutant.
- 25 There is a clear difference in the amount of respective recombinant proteins necessary to reach 50% inhibition of the binding to serum IgE present in the serum pool. Recombinant *Bet v 1* reaches 50% inhibition at about 6.5 ng whereas the corresponding concentration for *Bet v 1*  
30 Pro108Gly is 15 ng. This show that the single point mutation introduced in *Bet v 1* Pro108Gly lowers the affinity for specific serum IgE by a factor of about 2.

The maximum level of inhibition reached by the *Bet v 1*  
35 Pro108Gly mutant is somewhat lower compared to recombinant *Bet v 1*. This may indicate that after the

Pro108Gly substitution, some of the specific IgE present in the serum pool are unable to recognise the Bet v 1 Pro108Gly mutant.

5 Bet v 1 mutant Glu60Ser (non-patch mutant)

Glutamic acid in position 60 show a high degree of solvent-exposure (60%) however, it is not located in a molecular surface patch common for *Fagales* allergens. A serine residue was found to occupy position 60 in some of the Bet v 1 homologous PR-10 proteins arguing for that glutamic acid can be replaced with serine without distortion of the  $\alpha$ -carbon backbone tertiary structure. In addition, as none of the naturally occurring isoallergen sequences have serine in position 60, the substitution of glutamic acid with serine gives rise to a non-naturally occurring Bet v 1 molecule.

20 IgE-binding properties of Bet v 1 Glu60Ser mutant

The IgE-binding properties of Bet v 1 Glu60Ser mutant was compared with recombinant Bet v 1 in a fluid-phase IgE-inhibition assay using the pool of serum IgE derived from birch allergic patients described above.

25 Figure 7 shows the inhibition of the binding of biotinylated recombinant Bet v 1 to serum IgE from a pool of allergic patients by non-biotinylated Bet v 1 and by Bet v 1 Glu60Ser mutant. In contrast to the Glu45Ser, Pro108Gly and Asn28Thr+Lys32Gln mutants, the substitution glutamic acid 60 to serine, does not shown any significant effect on the IgE-binding properties of. This indicates that substitutions outside the defined *Fagales* common patches only have a marginal effect on the binding of specific serum IgE supporting the concept that conserved allergen molecular surface areas harbours

dominant IgE-binding epitopes.

#### Bet v 1 Triple-patch mutant

5 In the Triple-patch mutant, the point mutations  
(Glu45Ser, Asn28Thr+Lys32Gln and Pro108Gly) introduced in  
the three different common *Fagales* patches, described  
above, were simultaneously introduced in creating an  
artificial mutant carrying four amino acid substitutions.

10

#### Structural analysis of Bet v 1 Triple-patch mutant

The structural integrity of the purified Triple-patch  
mutant was analysed by circular dichroism (CD)  
15 spectroscopy. Figure 8 shows the CD spectra of  
recombinant and Triple-patch mutant, recorded at close  
to equal concentrations. The overlap in peak amplitudes  
and positions in the CD spectra from the two recombinant  
proteins shows that the two preparations contain equal  
20 amounts of secondary structures strongly suggesting that  
the  $\alpha$ -carbon backbone tertiary structure is not affected  
by the introduced amino acid substitutions.

#### IgE-binding properties of Bet v 1 Triple-patch mutant

25

The IgE-binding properties of Bet v 1 Triple-patch mutant  
was compared with recombinant Bet v 1 in a fluid-phase  
IgE-inhibition assay using the pool of serum IgE derived  
from birch allergic patients described above.

30

Figure 9 shows the inhibition of the binding of  
biotinylated recombinant Bet v 1 to serum IgE from a pool  
of allergic patients by non-biotinylated Bet v 1 and by  
Bet v 1 Triple-patch mutant. In contrast to the single  
35 mutants described above, the inhibition curve of the  
Triple-patch mutant is no longer parallel relative to

recombinant. This shows that the substitutions introduced in the Triple-patch mutant has changed the IgE-binding properties and epitope profile compared to recombinant. The lack of parallelity makes it difficult to quantify the decrease of the Triple-patch mutant affinity for specific serum IgE.

Recombinant *Bet v 1* reaches 50% inhibition at about 6 ng whereas the corresponding concentration for *Bet v 1* Triple-patch mutant is 30 ng, i.e a decrease in affinity by a factor 5. However, in order to reach 80% inhibition the corresponding values are 20 ng and 400 ng, respectively, i.e a decrease by a factor 20.

T cell proliferation assay using recombinant *Bet v 1* Triple-patch mutant

The analysis was carried out as described in ref. 15. It was found that recombinant *Bet v 1* Triple-patch mutant was able to induce proliferation in T cell lines from three different birch pollen allergic patients with stimulation indices similar to recombinant and naturally occurring. This suggests that the Triple-patch mutant can initiate the cellular immune response necessary for antibody production.

EXAMPLE 2

Identification of common epitopes within *Vespula vulgaris* venom major allergen antigen 5

Antigen 5 is one of the three vespid venom proteins, which are known allergens in man. The vespids include hornets, yellow-jacket and wasps. The other two known allergens of vespid venoms are phospholipase A<sub>1</sub> and hyaluronidase. Antigen 5 from *Vespula vulgaris* (Ves v 5)

has been cloned and expressed as recombinant protein in the yeast system (Monsalve et al. 1999, ref. 22). The three-dimensional crystal structure of recombinant Ves v 5 has recently been determined at 1.8 Å resolution (in preparation). The main features of the structure consist of four  $\beta$ -strands and four  $\alpha$ -helices arranged in three stacked layers giving rise to a " $\alpha$ - $\beta$ - $\alpha$  sandwich". The sequence identity between Antigen 5 homologous allergens from different *Vespula* species is about 90% suggesting presence of conserved molecular surface areas and B cell epitopes.

The presence and identification of common patches was performed after alignment of all known amino acid sequences, as previously described for tree pollen allergens, of the *Vespula* antigen 5 allergens in combination with an analysis of the molecular surface of Antigen 5 revealed by the three-dimensional structure of Ves v 5. Figure 10 shows solvent accessibility of individually aligned antigen 5 residues and alignment of *Vespula* antigen 5 sequences (left panel). On the right panel of figure 10 is shown the molecular surface of antigen 5 with conserved areas among *Vespula* antigen 5:s coloured.

#### Selection of amino acid residues for site-directed mutagenesis

Amino acid residues for site-directed mutagenesis were selected among residues present the patches common for *Vespula* since modifications of these is expected to affect the binding of serum IgE from the majority of patients showing clinical *Vespula* allergic cross-reactivity.

The relative orientation and percentage of solvent-

exposure of each amino acid residue within respective patch was calculated based on their atomic coordinates. Residues having a low degree of solvent exposure were not regarded suitable for mutagenesis due to the possible  
5 disruption of the structure or lack of antibody interaction. The remaining residues were ranked according to their degree of solvent-exposure.

#### Cloning of the gene encoding Ves v 5

10

Total RNA was isolated from venom acid glands of *Vespula vulgaris* vespids as described in (Fang et al. 1988, ref. 23).

15

First-strand cDNA synthesis, PCR amplification and cloning of the Ves v 5 gene was performed as described in (Lu et al. 1993, ref. 24)

#### Subcloning into pPICZαA

20

The gene encoding Ves v 5 was subsequently sub-cloned into the pPICZαA vector (Invitrogen) for secreted expression of Ves v 5 in *Pichia pastoris*. The gene was amplified by PCR and sub-cloned in frame with the coding  
25 sequence for the α-factor secretion signal of *Saccharomyces cerevisiae*. In this construct the α-factor is cleaved off, *in vivo*, by the *Pichia pastoris* Kex2 protease system during secretion of the protein.

30

In brief PCR was performed using Ves v 5 as template and primers corresponding to the amino- and carboxyterminus of the protein, respectively. The primers were extended in the 5'-end to accommodate restriction sites for cloning, EcoRI and XbaI, respectively. Nucleotides  
35 encoding the Kex2 cleavage site was in this construct positioned 18 nucleotides upstream to the amino terminus

of the protein, resulting in the expression of Ves v 5 with six additional amino acids, Glu-Ala-Glu-Ala-Glu-Phe, at the amino terminus.

5    Insertion of pPICZ $\alpha$ A-Ves v 5 into *P. pastoris*

The pPICZ $\alpha$ A vectors with the Ves v 5 gene inserted was linearised by Sac I restriction and inserted into the AOX1 locus on the *Pichia pastoris* genome. Insertion was performed by homologous recombination on *Pichia pastoris* KM71 cells following the recommendations of Invitrogen.

In vitro mutagenesis

15    In vitro mutagenesis was performed by PCR using recombinant pPICZ $\alpha$ A with Ves v 5 inserted as template. Each mutant Ves v 5 gene was generated by 3 PCR reactions using 4 primers.

20    Two mutation-specific oligonucleotide primers were synthesised accommodating each mutation, one for each DNA strand, see Figures 11 and 12. Using the mutated nucleotide(s) as starting point both primers were extended 6-7 nucleotides in the 5'-end and 12-13  
25    nucleotides in the 3'-end. The extending nucleotides were identical in sequence to the Ves v 5 gene in the actual region.

Two generally applicable primers (denoted "all sense" and  
30    "all non-sense" in Figure 12) were furthermore synthesised and used for all mutants. To insure expression of Ves v 5 mutants with authentic amino terminus, one primer corresponding to the amino terminus of the protein was extended in the 5'-end with a Xho I  
35    site. Upon insertion of the Ves v 5 mutant genes into the pPICZ $\alpha$ A vector, the Kex2 protease cleavage site was

regenerated directly upstream to the amino terminus of Ves v 5. The second primer was corresponding in sequence to a region of the pPICZ $\alpha$ A vector positioned approximately 300 bp downstream from the Ves v 5 gene.

5 The sequence of the primer corresponding to the amino terminus of Ves v 5 is derived from the sense strand and the sequence of the downstream primer is derived from the non-sense strand, see Figure 11.

10 Two independent PCR reactions were performed essentially according to standard procedures (Saiki et al 1988) with the exception that only 20 temperature cycles were performed in order to reduce the frequency of PCR artefacts. Each PCR reaction used pPICZ $\alpha$ A with Ves v 5

15 inserted as template and one mutation-specific and one generally applicable primer in meaningful combinations.

The PCR products were purified by using "Concert, Rapid PCR Purification System" (Life Technologies). A third PCR

20 reaction was performed using the combined PCR products from the first two PCR reactions as template and both generally applicable primers. Again, 20 cycles of standard PCR were used. The PCR product was purified with the "Concert, Rapid PCR Purification System" (Life

25 Technologies), cut with restriction enzymes (*XhoI/XbaI*), and ligated directionally into pPICZ $\alpha$ A vector restricted with the same enzymes. Figure 13 shows an overview of all Ves v 5 mutations.

30 Insertion of pPICZ $\alpha$ A-Ves v 5 mutants into *P. pastoris*

The pPICZ $\alpha$ A vectors with the Ves v 5 mutant genes inserted were linearised by Sac I restriction and inserted into the AOX1 locus on the *Pichia pastoris*

35 genome. Insertions were performed by homologous recombination on *Pichia pastoris* KM71 cells following the

recommendations of Invitrogen.

#### Nucleotide sequencing

5 Determination of the nucleotide sequence of the Ves v 5 encoding gene was performed before and after subcloning, and following *in vitro* mutagenesis, respectively.

Plasmid DNA's from 10 ml of bacterial culture grown to  
10 saturation overnight in LB medium supplemented with 0.1 g/l ampicillin were purified on Qiagen-tip 20 columns and sequenced using the Sequenase version 2.0 DNA sequencing kit (USB) following the recommendations of the suppliers.

#### 15 Expression and purification of recombinant Ves v 5

Recombinant yeast cells of *Pichia pastoris* strain KM71 were grown in 500 ml bottles containing 100 ml of pH 6.0 phosphate buffer containing yeast nitrogen base, biotin,  
20 glycerol and histidine at 30°C with orbital shaking at 225 rpm until  $A_{500\text{ nm}}$  of 4-6. Cells were collected by centrifugation and re-suspended in 10 ml of similar buffered medium containing methanol in place of glycerol. Incubation was continued at 30°C for 7 days with daily  
25 addition of 0.05 ml methanol.

Cells were harvested by centrifugation and the collected culture fluid was concentrated by ultrafiltration. After dialysis against 50 mM ammonium acetate buffer, pH 4.6,  
30 the sample was applied to a FPLC (Pharmacia) SE-53 cation exchange column equilibrated in the same buffer. The column was eluted with a 0-1.0 M NaCl, 50 mM ammonium acetate linear gradient. The recombinant Ves v 5 peak eluting at about 0.4 M NaCl was collected and dialysed  
35 against 0.02 N acetic acid. After concentration to about 10 mg/ml, the purified Ves v 5 was stored at 4°C.

### Crystallisation of recombinant Ves v 5

Crystals of Ves v 5 was grown by the vapour diffusion  
5 technique at 25°C. For crystallisation, 5 µl of 5 mg/ml  
Ves v 5 was mixed with 5 µl of 18% PEG 6000, 0.1 M sodium  
citrate, pH 6.0 and equilibrated against 1 ml of 18% PEG  
6000, 0.1 M sodium citrate, pH 6.0.

10 X-ray diffraction data was collected at 100K from native  
Ves v 5 crystals and after incorporation of heavy-atom  
derivatives and used to solve the three-dimensional  
structure of Ves v 5, see Figure 10 (manuscript in  
preparation).

15

### Immuno-electrophoresis using rabbit polyclonal antibodies

The two Ves v 5 mutants were produced as recombinant Ves  
v 5 proteins and tested for their reactivity towards  
20 polyclonal rabbit antibodies raised against recombinant  
Ves v 5. When analysed by rocket immuno-electrophoresis  
under native conditions, the rabbit antibodies were able  
to precipitate recombinant Ves v 5 as well as both  
mutants, indicating that the mutants have conserved  $\alpha$ -  
25 carbon backbone tertiary structure.

### Inhibition of specific serum IgE

The IgE-binding properties of Ves v 5 mutants were  
30 compared to recombinant Ves v 5 in a fluid-phase IgE-  
inhibition assay using a pool of serum IgE derived from  
vespid venom allergic patients.

The inhibition assay was performed as described above  
35 using biotinylated recombinant Ves v 5 instead of Bet v  
1.

Ves v 5 Lys72Ala mutant

Lysine in position 72 show a high degree of solvent-exposure (70%) and is located in a molecular surface patch common for *Vespula* antigen 5. The relative orientation and high degree of solvent exposure argued for that lysine 72 can be replaced by an alanine residue without distortion of the  $\alpha$ -carbon backbone tertiary structure. In addition, as none of the naturally occurring isoallergen sequences have alanine in position 72, the substitution of lysine with alanine gives rise to a non-naturally occurring Ves v 5 molecule.

IgE-binding properties of Ves v 5 Lys72Ala mutant

The IgE-binding properties of Ves v 5 Lys72Ala mutant was compared with recombinant Ves v 5 in a fluid-phase IgE-inhibition assay using the pool of serum IgE derived from birch allergic patients described above.

Figure 14 shows the inhibition of the binding of biotinylated recombinant Ves v 5 to serum IgE from a pool of allergic patients by non-biotinylated Ves v 5 and by Ves v 5 Lys72Ala mutant.

There is a clear difference in the amount of respective recombinant proteins necessary to reach 50% inhibition of the binding to serum IgE present in the serum pool. Recombinant Ves v 5 reaches 50% inhibition at about 6 ng whereas the corresponding concentration for Ves v 5 Lys72Ala mutant is 40 ng. This show that the single point mutation introduced in Ves v 5 Lys72Ala mutant lowers the affinity for specific serum IgE by a factor of about 6. The maximum level of inhibition reached by the Ves v 5 Lys72Ala mutant significantly lower compared to

recombinant Ves v 5. This may indicate that after the Lys72Ala substitution, some of the specific IgE present in the serum pool are unable to recognise the Ves v 5 Lys72Ala mutant.

5

#### Ves v 5 Tyr96Ala mutant

Tyrosine in position 96 show a high degree of solvent-exposure (65%) and is located in a molecular surface patch common for *Vespula* antigen 5. The relative orientation and high degree of solvent exposure argued for that tyrosine 96 can be replaced by an alanine residue without distortion of the three-dimensional structure. In addition, as none of the naturally occurring isoallergen sequences have alanine in position 96, the substitution of tyrosine with alanine gives rise to a non-naturally occurring Ves v 5 molecule.

20

#### IgE-binding properties of Ves v 5 Tyr96Ala mutant

The IgE-binding properties of Ves v 5 Tyr96Ala mutant was compared with recombinant Ves v 5 in a fluid-phase IgE-inhibition assay using the pool of serum IgE derived from birch allergic patients described above.

25

Figure 14 shows the inhibition of the binding of biotinylated recombinant Ves v 5 to serum IgE from a pool of allergic patients by non-biotinylated Ves v 5 and by Ves v 5 Tyr96Ala mutant.

30

There is a clear difference in the amount of respective recombinant proteins necessary to reach 50% inhibition of the binding to serum IgE present in the serum pool. Recombinant Ves v 5 reaches 50% inhibition at about 6 ng whereas the corresponding concentration for Ves v 5 Tyr96Ala mutant is 40 ng.

35

This show that the single point mutation introduced in Ves v 5 Tyr96Ala mutant lowers the affinity for specific serum IgE by a factor of about 6.

5

The maximum level of inhibition reached by the Ves v 5 Tyr96Ala mutant significantly lower compared to recombinant Ves v 5. This may indicate that after the Tyr96Ala substitution, some of the specific IgE present in the serum pool are unable to recognise the Ves v 5 Tyr96Ala mutant.

10

## REFERENCES

1. WO 97/30150 (Pangenetics B.V., Molecules for the induction of immunological tolerance)
- 5 2. WO 92/02621 (Biomay Biotechnik Produktions- und Handelsgesellschaft mbH, Allergens of Alder pollen and applications thereof)
- 10 3. WO 90/11293 (Immunologic Pharmaceutical Corporation, The University of North Carolina at Chapel Hill, Allergenic proteins from ragweed and uses thereof)
- 15 4. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, Okudaira H, Okumura Y: "Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy". Nat Biotechnol 15, 754-758 (1997).
- 20 5. Smith AM, Chapman MD: "Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues". Clin Exp Allergy 27, 593-599 (1997).
- 25 6. Aki T, Ono K, Hidaka Y, Shimonishi Y, Jyo T, Wada T, Yamashita M, Shigeta S, Murooka Y, Oka S: "Structure of IgE epitopes on a new 39-kD allergen molecule from the house dust mite, *Dermatophagoides farinae*". Int Arch Allergy Immunol 103, 357-364 (1994).
- 30 7. Förster E, Dudler T, Gmachl M, Aberer W, Urbanek R, Suter M: "Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy". J Allergy Clin Immunol 95, 1229-1235 (1995).
- 35

8. Burks AW, Shin D, Cockrell G, Stanley JS, Helm RM, Bannon GA: "Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity". Eur J Biochem 245, 334-339 (1997).
9. Stanley JS, King N, Burks AW, Huang SK, Sampson H, Cockrell G, Helm RM, West CM, Bannon GA: "Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2". Arch Biochem Biophys 342, 244-253 (1997).
10. Ferreira F, Rohlf s A, Hoffmann-Sommergruber K, Schenk S, Ebner C, Briza P, Jilek A, Kraft D, Breitenbach M, Scheiner O: "Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis". Adv Exp Med Biol 409, 127-135 (1996).
11. Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm R, Jah-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger H-J, Scheiner O, "Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypeallergenic variants for immunotherapy", FASEB Journal for Experimental Biology Vol. 12, No. 2, February 1998, 231-242 (1998).
12. Wiedemann P, Giehl K, Almo SC, Fedorov AA, Girvin M, Steinberger P, Rüdiger M, Ortner M, Sippl M, Dolecek C, Kraft D, Jockusch B, Valenta R: "Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody". J Biol Chem 271, 29915-29921 (1996).
13. Alvarez AM, Fukuhara E, Nakase M, Adachi T, Aoki N, Nakamura R, Matsuda T: "Four rice seed cDNA clones belonging to the alpha-amylase/trypsin inhibitor gene

family encode potential rice allergens". *Biosci Biotechnol Biochem* 59, 1304-1308 (1995).

14. Colombo P, Kennedy D, Ramsdale T, Costa MA, Djro G,  
5 Izzo V, Salvadori S, Guerrini R, Cocchiara R, Mirisola  
MG, Wood S, Geraci D, *Journal of Immunology* Vol. 160, No.  
6, 15 March 1998, 2780-2875.
15. Spangfort MD, Ipsen H, Sparholt SH, Aasmul-Olsen S,  
10 Larsen MR, Mørtz E, Roepstorff P, Larsen JN: "Characteri-  
zation of Purified Recombinant Bet v 1 with Authentic N-  
terminus, Cloned in Fusion with Maltose-Binding Protein".  
*Prot Exp Purification* 8, 365-373 (1996a).
- 15 16. Ipsen H, Wihl J-Å, Petersen BN, Løwenstein H:  
"Specificity mapping of patients IgE response towards the  
tree pollen major allergens Aln g I, Bet v I and Cor a  
I." *Clin. Exp. Allergy* 22, 391-9, (1992)
- 20 17. Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN,  
Joost van Neerven RJ, Schou C, Løwnstein H, and Spangfort  
MD: "X-ray and NMR structure of Bet v 1, the origin of  
birch pollen allergy". *Nature structural biology* 3, 1040-  
1045 (1996).
- 25 18. Altschul SF, Gish W, Miller W, Myers EW, and Lipman  
DJ: "Basic local alignment search tool". *J. Mol. Biol.*  
215, 403-410 (1990).
- 30 19. Higgins D, Thompson J, Gibson T, Thompson JD, Higgins  
DG, and Gibson TJ: "CLUSTAL W: improving the sensitivity  
of progressive multiple sequence alignment through  
sequence weighting, position-specific gap penalties and  
weight matrix choice". *Nucleic Acids Res.* 22, 4673-4680  
35 (1994).

20. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase". Science 239, 487-491 (1988).

5

21. Spangfort MD, Larsen JN, Gajhede M: "Crystallization and Preliminary X-ray Investigation at 2.0 Å Resolution of *Bet v 1*, a Birch Pollen Protein Causing IgE-Mediated Allergy". PROTEINS, Struct Func Genet 26, 358-360 (1996b).

10

22. Monsalve RI, Lu G, and King TP: "Recombinant venom allergen, antigen 5 of yellowjacket (*Vespula vulgaris*) and paper wasp (*Polistes annularis*) by expression in bacteria or yeast" (1999) Submitted.

15

23. Fang KSF, Vitale M, Fehlner P and King TP: "cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5". Proc. Natl. Acad. Sci. USA 85, 895 (1988).

20

24. Lu G, Villalba M, Coscia MR, Hoffman DR and King TP: "Sequence Analysis and Antigenic Cross-reactivity of a Venom Allergen, Antigen 5, from Hornets, Wasps, and Yellow Jackets". Journal of Immunology 150, 2823-2830

25

(1993).

## CLAIMS

1. Recombinant allergen, characterised in that it is a non-naturally occurring mutant derived from a naturally occurring allergen, wherein at least one surface-exposed, conserved amino acid residue of a B cell epitope is substituted by another residue which does not occur in the same position in the amino acid sequence of any known homologous protein within the taxonomic order from which said naturally occurring allergen originates, said mutant allergen having essentially the same  $\alpha$ -carbon backbone tertiary structure as said naturally occurring allergen, and the specific IgE binding to the mutated allergen being reduced as compared to the binding to said naturally occurring allergen.

2. Recombinant allergen according to claim 1, characterised in that it is obtainable by

a) identifying amino acid residues in a naturally occurring allergen which are conserved with more than 70% identity in all known homologous proteins within the taxonomic order from which said naturally occurring allergen originates;

b) defining at least one patch of conserved amino acid residues being coherently connected over at least 400  $\text{\AA}^2$  of the surface of the three-dimensional structure of the allergen molecule as defined by having a solvent accessibility of at least 20 %, said at least one patch comprising at least one B cell epitope; and

c) substituting at least one amino acid residue in said at least one patch by another amino acid being non-conservative in the particular position while essentially preserving the overall  $\alpha$ -carbon backbone tertiary

structure of the allergen molecule.

3. Recombinant allergen according to claim 1 or 2, characterised in that the specific IgE binding to the mutated allergen is reduced by at least 5%, preferably at least 10%.

4. Recombinant allergen according to any of claims 1-3, characterised in that when comparing the  $\alpha$ -carbon backbone tertiary structures of the mutant and the naturally occurring allergen molecules, the average root mean square deviation of the atomic coordinates is below 2Å.

5. Recombinant allergen according to claim 2, characterised in that said at least one patch comprises atoms of 15-25 amino acid residues.

6. Recombinant allergen according to any one of claims 2-5, characterised in that the amino acid residues of said at least one patch are ranked with respect to solvent accessibility, and one or more amino acids among the more solvent accessible ones are substituted.

7. Recombinant allergen according to claim 6, characterised in that one or more amino acid residues of said at least one patch having a solvent accessibility of 20-80 % are substituted.

8. Recombinant allergen according to any one of claims 2-7, characterised in that 1-5 amino acid residues per 400 Å<sup>2</sup> in said at least one patch are substituted.

9. Recombinant allergen according to any one of claims 2-5, characterised in that the substitution of one or more amino acid residues in said B cell epitope or said

at least one patch is carried out by site-directed mutagenesis.

10. Recombinant allergen according to any one of claims  
5 1-9, characterised in that it is derived from an inhalation allergen.

11. Recombinant allergen according to claim 10,  
characterised in that it is derived from a pollen  
10 allergen.

12. Recombinant allergen according to claim 10,  
characterised in that it is derived from a pollen  
allergen originating from the taxonomic order of *Fagales*,  
15 *Oleales* or *Pinales*.

13. Recombinant allergen according to claim 12,  
characterised in that it is derived from *Bet v 1*.

20 14. Recombinant allergen according to claim 13,  
characterised in that at least one amino acid residue of  
said B cell epitope or said at least one patch is  
substituted.

25 15. Recombinant allergen according to claim 14,  
characterised in that the substitution(s) is (are)  
Thr10Pro, Asp25Gly, (Asn28Thr + Lys32Gln), Glu45Ser,  
Asn47Ser, Lys55Asn, Thr77Ala, Pro108Gly or (Asn28Thr,  
Lys32Gln, Glu45Ser, Pro108Gly).

30

16. Recombinant allergen according to claim 11,  
characterised in that it is derived from a pollen  
allergen originating from the taxonomic order of *Poales*.

35 17. Recombinant allergen according to claim 11,  
characterised in that it is derived from a pollen

allergen originating from the taxonomic order of *Asterales* or *Urticales*.

18. Recombinant allergen according to claim 10,  
5 characterised in that it is derived from a house dust mite allergen.

19. Recombinant allergen according to claim 18,  
characterised in that it is derived from a mite allergen  
10 originating from *Dermatophagoides*.

20. Recombinant allergen according to claim 10,  
characterised in that it is derived from a cockroach  
allergen.

15 21. Recombinant allergen according to claim 10,  
characterised in that it is derived from an animal  
allergen.

20 22. Recombinant allergen according to claim 21,  
characterised in that it is derived from an animal  
allergen originating from cat, dog or horse.

23. Recombinant allergen according to any one of claims  
25 1-9, characterised in that it is derived from a venom  
allergen.

24. Recombinant allergen according to claim 23,  
characterised in that it is derived from a venom allergen  
30 originating from the taxonomic order of *Hymenoptera*.

25. Recombinant allergen according to claim 24,  
characterised in that it is derived from a venom allergen  
from the taxonomic order of *Vespidae*, *Apidae* and  
35 *Formicoidae*.

26. Recombinant allergen according to any one of claims 23-25, characterised in that it is derived from Ves v 5.

27. Recombinant allergen according to any one of claims  
5 23-26, characterised in that at least one amino acid is substituted.

28. Recombinant allergen according to any one of claims  
25-27, characterised in that the substitution is Lys72Ala  
10 or Tyr96Ala.

29. A method of preparing a recombinant allergen according to any one of claims 1-29, characterised by

15 a) identifying amino acid residues in a naturally occurring allergen which are conserved with more than 70% identity in all known homologous proteins within the taxonomic order from which said naturally occurring allergen originates;

20 b) defining at least one patch of conserved amino acid residues being coherently connected over at least 400 Å<sup>2</sup> of the surface of three-dimensional structure of the allergen molecule as defined by having a solvent  
25 accessibility of at least 20%, said at least one patch comprising at least one B cell epitope; and

c) substituting at least one amino acid residue in said at least one patch by another amino acid being non-conservative in the particular position while essentially  
30 preserving the overall α-carbon backbone tertiary structure of the allergen molecule.

30. A method according to claim 29, characterised by  
35 ranking the amino acid residues of said at least one patch with respect to solvent accessibility and

substituting one or more amino acids among the more solvent accessible ones.

31. A method according to claim 29 or 30, characterised  
5 in that the substitution of one or more amino acid residues in said B cell epitope or said at least one patch is carried out by site-directed mutagenesis.

32. Recombinant allergen according to any of claims 1-28  
10 for use as a pharmaceutical.

33. Pharmaceutical composition, characterised in that it comprises a recombinant allergen according to any one of claims 1-28, optionally in combination with a  
15 pharmaceutically acceptable carrier and/or excipient, and optionally an adjuvant.

34. A pharmaceutical composition according to claim 33, characterised in that it is in the form of a vaccine  
20 against allergic reactions elicited by a naturally occurring allergen in patients suffering from allergy.

35. Method of generating an immune response in a subject comprising administering to the subject at least one  
25 recombinant allergen according to any one of claims 1-28 or a pharmaceutical composition according to any one of claims 33-34.

36. Process for preparing a pharmaceutical composition  
30 according to any one of claims 33-34 comprising mixing at least one recombinant allergen according to any one of claims 1-28 with pharmaceutically acceptable substances and/or excipients.

37. Vaccination or treatment of a subject comprising  
35 administering to the subject at least one recombinant

allergen according to any one of claims 1-28 or a pharmaceutical composition according to any one of claims 33-34.

5 38. Pharmaceutical composition obtainable by the process according to claim 36.

39. Method for the treatment, prevention or alleviation of allergic reactions comprising administering to a  
10 subject a recombinant allergen according to any one of claims 1-28 or a pharmaceutical composition according to any one of claims 33-34 or 38.

1/14

**Fig. 1**

Mutant-specific oligonucleotide primers used for mutant number 1. Mutated nucleotide underlined.

Bet v 1 sense	5'- AATTATGAGACTGAGACCA <u>C</u> CTCTGTTATCCCAGCAGCTCG	-3'
Bet v 1 non-sense	3'- TTAATACTCTGACTCTGGT <u>G</u> GAGACAATAGGGTCGTCGAGC	-5'
sense primer	5'- TGAGACCC <u>C</u> CTCTGTTATCCCAG	-3'
non-sense primer	3'- ATACTCTGACTCTGGGGGAGACA	-5'

2/14

Fig. 2

Oligonucleotide primers for site directed mutagenesis of  
Bet v 1 (No. 2801).

all	sense	1: 183Bv, 15-mer 5'-GTTGCCAACGATCAG
1	sense	2: 184Bv, 23-mer 5'-TGAGACCCCTCTGTTATCCCAG
1	non-sense	3: 185Bv, 23-mer 5'-ACAGAGGGGTCTCAGTCTCATA
2	sense	4: 186Bv, 31-mer 5'-GATACCCTCTTCCACAGGTGCACCCCAAG
2	non-sense	5: 187Bv, 31-mer 5'-ACCTGTGGAAAGAGGTATCGCCATCAAGGA
3	sense	6: 188Bv, 23-mer 5'-AACATTTTCAGGAAATGGAGGGCC
3	non-sense	7: 189Bv, 23-mer 5'-TTTCCTGAAATGTTTTCAACACT
4	sense	8: 190Bv, 23-mer 5'-TTAAGAACATCAGCTTTCCCGAA
4	non-sense	9: 191Bv, 23-mer 5'-AGCTGATGTTCTTAATGGTTCCA
5	sense	10: 192Bv, 23-mer 5'-GGACCATGCAAACCTCAAATACA
5	non-sense	11: 193Bv, 23-mer 5'-AGTTTGCATGGTCCACCTCATCA
6	sense	12: 194Bv, 23-mer 5'-TTTCCTCAGGCCTCCCTTTCAA
6	non-sense	13: 195Bv, 23-mer 5'-AGGCCTGAGGAAAGCTGATCTT
7	sense	14: 196Bv, 24-mer 5'-TGAAGGATCTGGAGGGCCTGGAAC
7	non-sense	15: 197Bv, 24-mer 5'-CCCTCCAGATCCTTCAATGTTTTC
8	sense	16: 198Bv, 24-mer 5'-GGCAACTGGTGATGGAGGATCCAT
8	non-sense	17: 199Bv, 24-mer 5'-CCATCACCAGTTGCCACTATCTTT
all	non-sense	18: 200Bv, 15-mer 5'-CATGCCATCCGTAAG

3/14

Fig. 3

## Overview of all Bet v 1 mutations

1 (A-C)	
GGTGTGTTTAATTATGAGACTGAGACC <u>AC</u> CTCTGTTATCCCAGCAGCTCGACTGTTCAAG	60
G V F N Y E T E T T-P S V I P A A R L F K	20
9 (A-G) 2 (A-C) 2 (A-C)	
GCCTTTATCCTTG <u>A</u> TGGCGATA <u>AC</u> CTCTTTCCAAAGGTTGCACCCCAAGCCATTAGCAGT	120
A F I L D-G G D N-T L F P K-Q V A P Q A I S S	40
3 (GA-TC) 7 (AA-TC) 4 (G-C) 6 (GA-TC)	
GTTGAAAACATTG <u>AA</u> GGAAATGGAGGGCCTGGAACCATTAAGAAGATCAGCTTTCCCGAA	180
V E N I E-S G N-S G G P G T I K K-N I S F P E-S	60
5 (CA-TG)	
GGCCTCCCTTTCAAGTACGTGAAGGACAGAGTTGATGAGGTGGACCAC <u>AC</u> AAACTTCAAA	240
G L P F K Y V K D R V D E V D H T-A N F K	80
TACAATTACAGCGTGATCGAGGGCGGTCCCATAGGCGACACATTGGAGAAGATCTCCAAC	
Y N Y S V I E G G P I G D T L E K I S N	100
10 (GAG-CAC) 8 (CCC-TGG)	
<u>GAG</u> ATAAAGATAGTGGCAAC <u>CCC</u> TGATGGAGGATCCATCTTGAAGATCAGCAACAAGTAC	360
E I K I V A T P-G D G G S I L K I S N K Y	120
CACACCAAAGGTGACCATGAGGTGAAGGCAGAGCAGGTTAAGGCAAGTAAAGAAATGGGC	
H T K G D H E V K A E Q V K A S K E M G	140
GAGACACTTTTGAGGGCCGTTGAGAGCTACCTCTTGGCACACTCCGATGCCTACAACATA	
E T L L R A V E S Y L L A H S D A Y N stop	159

4/14




Fig. 4

SUBSTITUTE SHEET (RULE 26)

5/14




Fig. 5 —◆— Bet v 1 —■— Asn28Thr+Lys32Gln

6/14




Fig. 6

SUBSTITUTE SHEET (RULE 26)

7/14




Fig. 7

8/14

10mM Na2HPO4/NaH2PO4 0, 02%Na3N3





FIG. 8

— 5798a r Betv 2801  
 --- 5797a 3xMutant 2585

9/14




Fig. 9

# Conserved residues among Vespula antigen 5









Figure 10.

11/14

Fig.11

Mutant-specific oligonucleotide primers used for Ves v 5 mutants.  
Mutated nucleotides underlined.

**Ves v 5 mutant 1 (K72A)**

Ves v 5 sense	5'-	ACCACAGCCTCCAGCGAAGAATATGAAAAATTTGGTATGGA	-3'
Ves v 5 non-sense	3'-	TGGTGTCTGGAGGTCGCTTCTTATACTTTTAAACCATACCT	-5'
sense primer	5'-	CCAGCGGCTAATATGAAAAAT	-3'
non-sense primer	3'-	GTCGGAGGTCGCCGATTATAC	-5'

---

**Ves v 5 mutant 2 (Y96A)**

Ves v 5 sense	5'-	GGCTAATCAATGTCAATATGGTCACGATACTTGCAGGGATG	-3'
Ves v 5 non-sense	3'-	CCGATTAGTTACAGTTATACCAGTGCTATGAACGTCCCTAC	-5'
sense primer	5'-	TGTCAAGCTGGTCACGATACT	-3'
non-sense primer	3'-	TTAGTTACAGTTCGACCACTG	-5'

---

12/14

Fig. 12

Oligonucleotide primers for site directed mutagenesis of Ves v 5.

all sense 1: XhoI start, 38-mer:

EcoRI  
 5'-CCGCTCGAGAAAAGAAACAATTATTGTAAAATAAAATG  
       L  E  K  R  N  N  Y  C  K  I  K  
       Kex2 cleavage site amino terminus of Ves v 5

1	sense	1: K72As	21-mer	5'-CCAGCGGCTAATATGAAAAAT
1	non-sense	2: K72Aa	21-mer	5'-CATATTAGCCGCTGGAGGCTG
2	sense	3: Y96As	21-mer	5'-TGTCAAGCTGGTCACGATACT
2	non-sense	4: Y96Aa	21-mer	5'-GTGACCAGCTTGACATTGATT
all non-sense		7: CT-pPICZαA,	21-mer	5'-ATTCATCAGCTGCGAGATAGG

Fig. 13

13/14

## Overview of Ves v 5 mutations

1	AACAATTATTGTAAAATAAAATGTTTGAAAGGAGGTGTCCATACTGCCTGCAAATATGGA	60
1	N N Y C K I K C L K G G V H T A C K Y G	20
61	AGTCTTAAACCGAATTGCGGTAATAAGGTAGTGGTATCCTATGGTCTAACGAAACAAGAG	120
21	S L K P N C G N K V V V S Y G L T K Q E	40
121	AAACAAGACATCTTAAAGGAGCACAATGACTTTAGACAAAAAATTGCACGAGGATTGGAG	180
41	K Q D I L K E H N D F R Q K I A R G L E	60
1 [K72A] (AAG-GCT)		
181	ACTAGAGGTAATCCTGGACCACAGCCTCCAGCGAAGAATATGAAAAATTTGGTATGGAAC	240
61	T R G N P G P Q P P A K N M K N L V W N	80
2 [Y96A] (TA-GC)		
241	GACGAGTTAGCTTATGTGCGCCCAAGTGTGGGCTAATCAATGTCAATATGGTCACGATACT	300
81	D E L A Y V A Q V W A N Q C Q Y G H D T	100
301	TGCAGGGATGTAGCAAAATATCAGGTTGGACAAAACGTAGCCTTAACAGGTAGCACGGCT	360
101	C R D V A K Y Q V G Q N V A L T G S T A	120
361	GCTAAATACGATGATCCAGTTAAACTAGTTAAAATGTGGGAAGATGAAGTGAAAGATTAT	420
121	A K Y D D P V K L V K M W E D E V K D Y	140
421	AATCCTAAGAAAAAGTTTTTCGGGAAACGACTTTCTGAAAACCGGCCATTACACTCAAATG	480
141	N P K K K F S G N D F L K T G H Y T Q M	160
481	GTTTGGGCTAACACCAAGGAAGTTGGTTGTGGAAGTATAAAATACATTCAAGAGAAATGG	540
161	V W A N T K E V G C G S I K Y I Q E K W	180
541	CACAAACATTACCTTGTATGTAATTATGGACCCAGCGGAACTTTAAGAATGAGGAACTT	600
181	H K H Y L V C N Y G P S G N F K N E E L	200
601	TATCAACAAAGTAA	612
201	Y Q T K stop	204

14/14




Fig. 14  
 ◆ r Ves v 5    ■ Lys72Ala    ▲ Tyr96Ala

1/14

Fig. 1

Mutant-specific oligonucleotide primers used for mutant number 1. Mutated nucleotide underlined.

Bet v 1 sense	5'- AATTATGAGACTGAGAC <u>C</u> CTCTGTTATCCCAGCAGCTCG	-3'
- Bet v 1 non-sense	3'- TTAATACTCTGACTCTGGTGGAGACAATAGGGTCCTCGAGC	-5'
sense primer	5'- TGAGACCCCTCTGTTATCCCAG	-3'
non-sense primer	3'- ATACTCTGACTCTGGGGAGACA	-5'

2/14

Fig. 2

Oligonucleotide primers for site directed mutagenesis of  
Bet v 1 (No. 2801).

all	sense	1: 183Ev, 15-mer 5'-GTTGCCAAGCATCAG
1	sense	2: 184Ev, 23-mer 5'-TGAGACCCCTCTGTTATCCCAAG
1	non-sense	3: 185Ev, 23-mer 5'-ACAGAGGGGCTCTCAGTCTCATA
2	sense	4: 186Ev, 31-mer 5'-GATACCTCTTTTCCACAGGTTGCACCCCAAG
2	non-sense	5: 187Ev, 31-mer 5'-ACCTGTGGAAABAGCTATCCCCATCAAGGA
3	sense	6: 188Ev, 23-mer 5'-AACATTTTCAGGAATGGAAGGCC
3	non-sense	7: 189Ev, 23-mer 5'-TTTCCTGAAATGTTTTCAACACT
4	sense	8: 190Ev, 23-mer 5'-TTAAGAACATCAGCTTTGCCCAA
4	non-sense	9: 191Ev, 23-mer 5'-AGCTGATGTTCTTAATGCTTCCN
5	sense	10: 192Ev, 23-mer 5'-GCACCTATCAAACTTCAAAATACA
5	non-sense	11: 193Ev, 23-mer 5'-AGTTTGATGCTTCACTTCATCA
6	sense	12: 194Ev, 23-mer 5'-TTTCCCTCAGGCTCTCTTTTCAA
6	non-sense	13: 195Ev, 23-mer 5'-AGGCTCAGGGAAGCTGATCTT
7	sense	14: 196Ev, 24-mer 5'-TGACGATCTCGAGGGCGGAGAAC
7	non-sense	15: 197Ev, 24-mer 5'-CCCTCCAGATCCTTCAATGPTTTC
8	sense	16: 198Ev, 24-mer 5'-GGCAACTCTCTGATCGAGATCCAT
8	non-sense	17: 199Ev, 24-mer 5'-CCATCACCAGTTCCCACTATCTTT
all	non-sense	18: 200Ev, 15-mer 5'-CATGCCATCCCTAAG

3/14

Fig. 3

## Overview of all Bet v 1 mutations

1(A-C)	
GGTGTGTTTAAATTATGAGACTGAGACCCAGCTCTGTATATCCAGGAGCTCGACTCTTCAGG	60
G V F W Y E T S T T P S V I P A A R L P K	20
5(A-B) 2(A-C) 2(A-D)	
GCCTTTATCTTCTGAGGGGAGATAAGCTCTTTCCAGAGGCTTCACCCCAAGCCATTAGCACT	120
A P I L D-G G D N-T L P P K-Q V L P Q A I S S	40
3(CA-TC) 7(AA-TC) 4(G-C) 6(GA-TC)	
CTTCAAAACATTTCAGAGGAGATCGAGGCGCTTGGAAACCATTAAGAGAGATCAGCTTTCCGGA	160
V E H I E-S G N-S G G P G T I K K-N I E P P E-S	60
5(CA-TG)	
GGCTTCCTTTTCAGCTACCTGACGACAGAGCTTCATGAGGTGGACCAAGCAAACTTCAGG	240
G L P F K Y V K D R V D E V D N T-A R P K	80
14(GAG-CAC) 8(CCC-TGG)	
GACATTACAGCCTGATGAGGCGGCTTCCATAGGCGACACATTCAGAGAGATCTCCAC	320
Y N Y S V I E C C F I G D T L E K I S N	100
14(GAG-CAC) 8(CCC-TGG)	
GACATTACAGCCTGATGAGGCGGCTTCCATAGGCGACACATTCAGAGAGATCTCCAC	360
E I K I V A T P-G D G G S I L K I S N K Y	120
14(GAG-CAC) 8(CCC-TGG)	
CACACCAAGCCTCAGCATCAGGCTCAGGCGAGGCACTTAAAGGCAAGTAAAGAAATGGBG	420
R T R C D H E V K A E Q V K A S K E H G	140
14(GAG-CAC) 8(CCC-TGG)	
CAGACACTTTTGGAGGCGCTTGAAGAGCTACCTCTTGGCAGACTTCGATGCTTACAACTAA	480
E T L L R A V E S Y L L N S D A Y N STOP	150

4/14




Fig. 4

5/14




Fig. 5 —◆— Bet v 1 —■— Asn28Thr+Lys32Gln

6/14




Fig. 6

SUBSTITUTE SHEET (RULE 26)

7/14




Fig. 7

8/14

10mM Na2HPO4/NaH2PO4 0.025M NaCl





FIG. 8

— 5798a r Baty 2501  
 --- 5797a 3M mutant 2505

SUBSTITUTE SHEET (RULE 25)

9/14




Fig. 9

10/14

# Conserved residues among Vespa vulgaris antigen 5





Figure 10.



11/14

Fig. 11

Mutant-specific oligonucleotide primers used for Ves v 5 mutants.  
Mutated nucleotides underlined.

## Ves v 5 mutant 1 (E72A)

Ves v 5 sense	5'-	ACCACAGCCTCCAGCGAAGAATATGAAAAATTGGTATGGA	-3'
Ves v 5 non-sense	3'-	TGGTGTCCGAGGCTCCCTTCTTATACTTTTAAACCATACCT	-5'
sense primer	5'-	CCAGCGGCTAATATGAAAAAT	-3'
non-sense primer	3'-	GTCGGAGGTCGCCCTTTATAC	-5'

---

## Ves v 5 mutant 2 (Y96A)

Ves v 5 sense	5'-	GGCTAATCAATGTCAATATGGTCACGATACTTGCAGGGATG	-3'
Ves v 5 non-sense	3'-	CCGATTAGTTACAGTTATACCAAGTGCTATGAACGTCCTTAC	-5'
sense primer	5'-	TGTCAAGCTGGTCACGATACT	-3'
non-sense primer	3'-	TTAGTTACAGTTTCGACCAAGTG	-5'

---

12/14

Fig. 12

Oligonucleotide primers for site directed mutagenesis of  
Ves v 5.

all sense 1: XhoI start, 28-mer:

EcoRI  
5'-CCGCTCGA~~AAAAAGAA~~CAATTATTGTAAAATAAAATG  
L E K G H N Y C R I K  
Kex2 cleavage site amino terminus of Ves v 5

1	sense	1: K72As	21-mer	5'-CCAGCGGCTAATATGAAAAAT
1	non-sense	2: K72As	21-mer	5'-CATATTAGCCGCTGGAGGCTG
2	sense	3: Y96As	21-mer	5'-TGTCAAGCTGCTCAGGATACT
2	non-sense	4: Y96As	21-mer	5'-GTGACCAGCTTGACATTGATT
all non-sense		7: CT-pPIC20A,	21-mer	5'-ATTCATCAGCTGCGAGATACG

Fig. 13

13/14

## Overview of Ves v 5 mutations

1	AACAATTATTGTAATAAATAATGTTTGAAGAGAGGTGTCCATACTGCCTGCAATATATGCA	60
1	N N Y C K I K C L K G G V H T A C K Y G	20
61	AGTCCTTAACCCGAATTGCGGTAAATAAGGTAGTGGTATCCCATGGTCTAACGAAACAAGAG	120
21	S L K P M C G N K V V V S Y G L T K Q E	40
121	AAACAAGACATCTTTAAAGGAGCACAATGACTTTAGACAAAAAATTGCACGAGGATTGGAG	180
41	K Q D I L K E H N D F R Q K I A R G L E	60
	1 [K72A] (AAG-GCT)	
181	ACTAGAGGTAATCCTGACCCACAGCCTCCAGCGAGGAATATGAAAAATTTGGTATGGAAC	240
61	T R C N P G P Q P P A E N M K N L V W N	80
	2 [Y96A] (TA-CC)	
241	GACGAGTTAGCTTATGTCCGCCAAGTGTGGGCTAATCAATGTCTATATGGTCCAGATACT	300
81	D E L A Y V A Q V W A N Q C Q Y G H D T	100
301	TGCAGCGATCTAGCAAAATATCAGGTTGACAAAACBTAGCCTTAACAGGTAGCACGGCT	360
101	C R D V A K Y Q V G Q N V A L T G S T A	120
361	GCTAAATACGATGATCCAGTTAAACTAGTTAAAAATGTGGGAAGATGAAGTGAAGATTAT	420
121	A K Y D D P V K L V K M W E D E V K D Y	140
421	AATCCTAAGAAAAAGTTTTCCGGGAAACGACTTTCTGAAAACCGGCCATTACACTCAATG	480
141	N P K K K F S G N D F L K T G H Y T Q M	160
481	GTTTGGGCTAACACCAAGGAAGTTGGTTGTGGAGTATATAAATACATTCAAGAGAAATGG	540
161	V W A N T K E V G C G S I K Y I Q E K W	180
541	CACAAACATTACCTTGTATGTAATTATGGACCCAGCGGAAACTTTAAGAAATGAGGAACCT	600
181	H K H Y L V C N Y G P S G N F K N E E L	200
601	TATCAACAAAATAA	612
201	Y Q T K stop	204



14/14




Fig. 14

SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/DK 99/00136

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/29 C12N15/12 C07K14/415 C07K14/435 A61K39/35  
A61K39/36

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>FERREIRA F ET AL.: "Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy" FASEB JOURNAL FOR EXPERIMENTAL BIOLOGY, vol. 12, no. 2, February 1998 (1998-02), pages 231-242, XP002085249 BETHESDA, MD US</p> <p>cited in the application</p> <p>page 240, right-hand column; figures 1,3</p> <p style="text-align: center;">--- -/--</p>	1-14,16, 29-39

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 August 1999

Date of mailing of the international search report

30/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

# INTERNATIONAL SEARCH REPORT

Inventor's Application No

PCT/DK 99/00136

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WIEDEMANN P ET AL.: "Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 47, 22 November 1996 (1996-11-22), pages 29915-29921, XP002085250</p> <p>MD US</p> <p>cited in the application</p> <p>page 29919; figure 6; table I</p>	1-12, 29-39
X	<p>SMITH A M AND CHAPMAN M D: "Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues"</p> <p>CLINICAL AND EXPERIMENTAL ALLERGY, vol. 27, no. 5, May 1997 (1997-05), pages 593-599, XP002085251</p> <p>cited in the application</p> <p>page 598, left-hand column, last paragraph; figure 1; table 2</p>	1-10, 18, 19, 21, 29-39
A	<p>WO 97 33910 A (THE ROCKEFELLER UNIVERSITY)</p> <p>18 September 1997 (1997-09-18)</p> <p>page 30, line 14 - line 30</p>	21, 23-26
A	<p>SPANGFORT M D ET AL.: "Three-dimensional structure and epitopes of Bet v 1"</p> <p>INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 113, no. 1-3, 1997, pages 243-245, XP002085253</p> <p>the whole document</p>	1-14, 29-39
A	<p>HOFFMAN D R: "ALLERGENS IN HYMENOPTERA VENOM XXV: THE AMINO ACID SEQUENCES OF ANTIGEN 5 MOLECULES AND THE STRUCTURAL BASIS OF ANTIGENIC CROSS -REACTIVITY"</p> <p>JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 92, no. 5, 1 November 1993 (1993-11-01), pages 707-716, XP002035181</p> <p>ISSN: 0091-6749</p> <p>page 715, left-hand column</p>	21, 23-26

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00136

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 35, 37 and 39  
are directed to a method of treatment of the human or animal  
body, the search has been carried out and based on the alleged  
effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In: 1st Application No

PCT/DK 99/00136

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9733910 A	18-09-1997	US 5804201 A AU 2320897 A	08-09-1998 01-10-1997
-----			

Form PCT/ISA/210 (patent family annex) (July 1992)